Virus cocktail takes on superbug in Last-Resort hip infection trial

NCT ID NCT06798168

AVAILABLE Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a personalized virus therapy (bacteriophage) combined with antibiotics in one patient with a chronic, drug-resistant hip joint infection. The patient has no other good options left—without treatment, the infection could be fatal or require leg amputation. The goal is to control the infection and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized bacteriophage cocktail (QDP-PSA-011) injected into the joint
What this could lead to: If it works, this could provide a way to control hard-to-treat joint infections without major surgery, potentially saving the patient's leg and life.
What could go wrong: This is a single-patient study, so results may not apply to others. The treatment is experimental, and there is no guarantee it will clear the infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PERIPROSTHETIC JOINT INFECTION OF THE RIGHT HIP DUE TO MULTIDRUG RESISTANT PSEUDOMONAS AERUGINOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial arthritis infective arthritis periprosthetic joint infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

JOINT INFECTION

Contacts and locations

Locations

The Ottawa Hospital
AVAILABLE

Ottawa, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.